Diarrhea pp 117-139 | Cite as

Protein-Losing Enteropathies

  • Jonathan Goldstein
  • Richard Wright
Part of the Clinical Gastroenterology book series (CG)


Protein-losing enteropathies are a syndrome caused by mucosal disruption or increased permeability or obstruction of lymphatic drainage. Documentation of excessive intestinal protein loss is the hallmark of the diagnosis. Treatment depends on the primary disease process and is usually a combination of dietary, medical, and/or surgical therapy. Most etiologies are treatable and may be curable if the primary disease is eliminated.

Key Words

Protein losing Enteropathy Exudative enteropathy Hypoalbuminemia Hypoproteinemia 


  1. 1.
    Greenwald DA. Protein-losing gastroenteropathy. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease, 8th ed. Philadelphia, PA: WB Saunders, 2006, pp. 557–562.Google Scholar
  2. 2.
    Farrell JJ. Digestion and absorption of nutrients and vitamins. In: Feldman M, Freidman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease, 8th ed. Philadelphia, PA: WB Saunders, 2006, Chapter 97.Google Scholar
  3. 3.
    Daniel H. Molecular and integrative physiology of intestinal peptide transport. Ann Rev Physiol 2004;66:361–384.CrossRefGoogle Scholar
  4. 4.
    Silk DB, Marrs TC, Addison JM. Absorption of amino acids from an amino acid mixture simulating casein and a tryptic hydrolysate of casein in man. Clin Sci Mol Med 1973;45:715–719.PubMedGoogle Scholar
  5. 5.
    Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am J Physiol Gastrointest Liver Physiol 2003; 285:G779–G788.PubMedGoogle Scholar
  6. 6.
    Silk DB, Grimble GK, Rees RG. Protein digestion and amino acid and peptide absorption. Proc Nutr Soc 1985;44:63–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Guandalini S, Frye RE, Tamer MA. Malabsorption syndromes. eMedicine from WebMD. Updated November 19, 2008. Available at
  8. 8.
    Waldmann TA, Wochner RD, Strober W. The role of the gastrointestinal tract in plasma protein metabolism. Studies with 51Cr Albumin. Am J Med 1969;46: 275–285.PubMedCrossRefGoogle Scholar
  9. 9.
    Strygler B, Nicar MJ, Santangelo WC, Porter JL, Fordtran JS. Alpha 1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990;99(5):1380–1387.PubMedGoogle Scholar
  10. 10.
    Freeman HJ, Kim YS, Sleisenger MH. Protein digestion and absorption in man. Normal mechanisms and protein–energy malnutrition. Am J Med 1979;67: 1030–1036.PubMedCrossRefGoogle Scholar
  11. 11.
    Milovic V, Grand RJ. Protein-losing gastroenteropathy. UpToDate 17.1 Referenced October 6, 2008. Available at
  12. 12.
    Kim KE. Protein-losing gastroenteropathy. In: Feldman M, Sleisenger MH, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease, 7th ed. Philadelphia, PA: WB Saunders, 2001. p. 446.Google Scholar
  13. 13.
    Landzberg BR, Pochapin MB. Protein-losing enteropathy and gastropathy. Curr Treat Options Gastroenterol 2001;4:39–49.PubMedCrossRefGoogle Scholar
  14. 14.
    Wochner RD, Weissman SM, Waldmann TA, Houston D, Berlin NI. Direct measurement of the rates of synthesis of plasma proteins in control subjects and patients with gastrointestinal protein loss. J Clin Invest 1968;47(5):971–982.PubMedCrossRefGoogle Scholar
  15. 15.
    Muller C, Wolf H, Gottlicher J, Zielinski CC, Eibl MM. Cellular immunodeficiency in protein-losing enteropathy. Predominant reduction of CD3+ and CD4+ lymphocytes. Dig Dis Sci 1991;36(1):116–122.PubMedCrossRefGoogle Scholar
  16. 16.
    Strober W, Wochner RD, Carbone PP, Waldmann TA. Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest 1967;46(10):1643–1656.PubMedCrossRefGoogle Scholar
  17. 17.
    Herfarth H, Hofstadter F, Feuerbach S, Jurgen SH, Scholmerich J, Rogler G. A case of recurrent gastrointestinal bleeding and protein-losing gastroenteropathy. Nat Clin Pract Gastroenterol Hepatol 2007;4(5):288–293.PubMedCrossRefGoogle Scholar
  18. 18.
    Takeda H, Ishihama K, Fukui T, Fujishima S, Orii T, Nakazawa Y, Shu HJ, Kawata S. Significance of rapid turnover proteins in protein-losing gastroenteropathy. Hepato-Gastroenterology 2003;50(54):1963–1965.PubMedGoogle Scholar
  19. 19.
    Malek NP, Ocran K, Tietge UJ, Maschek H, Gratz KF, Trautwein C, Wagner S, Manns MP. A case of the yellow nail syndrome associated with massive chylous ascites, pleural and pericardial effusions. Z Gastroenterol 1996;34(11):763–766.PubMedGoogle Scholar
  20. 20.
    Kelly DG, Miller LJ, Malagelada JR, Huizenga KA, Markowitz H. Giant hypertrophic gastropathy (Menetrier’s disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982;83(3):581–589.PubMedGoogle Scholar
  21. 21.
    Meuwissen SG, Ridwan BU, Hasper HJ, Innemee G. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch Menetrier Study Group. Scand J Gastroenterol Suppl 1992;194:1–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Warshauer DM, Thornton FJ, Nelson RC, O’Connor JB. Image of the month. Menetrier disease with premalignant transformation. Gastroenterology 2002; 123(4):968, 1419.PubMedCrossRefGoogle Scholar
  23. 23.
    Cardenas A, Kelly C. Menetrier disease. Gut 2004;53(3):330, 338.PubMedCrossRefGoogle Scholar
  24. 24.
    Bayerdorffer E, Ritter MM, Hatz R, Brooks W, Ruckdeschel G, Stolte M. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori―is Helicobacter pylori a pathogenic factor in Menetrier’s disease? Gut 1994;35(5):701–704.PubMedCrossRefGoogle Scholar
  25. 25.
    Di Vita G, Patti R, Aragona F, Leo P, Montalto G. Resolution of Menetrier’s disease after Helicobacter pylori eradication therapy. Dig Dis 2001;19(2):179–183.PubMedCrossRefGoogle Scholar
  26. 26.
    Yoshikawa I, Murata I, Tamura M, Kume K, Nakano S, Otsuki M. A case of protein-losing gastropathy caused by acute Helicobacter pylori infection. Gastrointest Endosc 1999;49(2):245–248.PubMedCrossRefGoogle Scholar
  27. 27.
    Waldmann TA, Wochner RD, Laster L, et al. Allergic gastroenteropathy: a cause of excessive protein loss. N Engl J Med 1967;276(14):762–769.PubMedCrossRefGoogle Scholar
  28. 28.
    Chehade M, Magid MS, Mofidi S, Nowak-Wegrzyn A, Sampson HA, Sicherer SH. Allergic eosinophilic gastroenteritis with protein-losing enteropathy: intestinal pathology, clinical course, and long-term follow-up. J Pediatr Gastroenterol Nutr 2006;42(5):516–521.PubMedCrossRefGoogle Scholar
  29. 29.
    Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. Mucosal histamine content and histamine secretion in Crohn’s disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995;108(2):127–133.PubMedCrossRefGoogle Scholar
  30. 30.
    Lake AM, Kagey-Sobotka A, Jakubowicz T, Lichtenstein LM. Histamine release in acute anaphylactic enteropathy of the rat. J Immunol 1984;133(3): 1529–1534.PubMedGoogle Scholar
  31. 31.
    Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosis. Rheumatology (Oxford) 1999;38(10):917–932. Review.CrossRefGoogle Scholar
  32. 32.
    Yaziki Y, Erkan D, Levine DM, Parker TS, Lockshin MD. Protein-losing enteropathy in systemic lupus erythematosis: report of a severe, persistent case and review of pathophysiology. Lupus 2002;11(2):119–123.CrossRefGoogle Scholar
  33. 33.
    Perednia DA, Curosh NA. Lupus-associated protein-losing enteropathy. Arch Intern Med 1990;150(9):1806–1810.PubMedCrossRefGoogle Scholar
  34. 34.
    Kim YG, Lee CK, Byeon JS, Myung SJ, Oh JS, Nah SS, Moon HB, Yoo B. Serum cholesterol in idiopathic and lupus-related protein-losing enteropathy. Lupus 2008;17(6):575–579.PubMedCrossRefGoogle Scholar
  35. 35.
    Benner KG, Montanaro A. Protein-losing enteropathy in systemic lupus erythematosis. Diagnosis and monitoring immunosuppressive therapy by alpha-1-antitrypsin clearance in stool. Dig Dis Sci 1989;34:132–135.PubMedCrossRefGoogle Scholar
  36. 36.
    Wang YF, Tseng KC, Chiu JS, Chuang MH, Chung MI, Lai NS. Outcome of surgical resection for protein-losing enteropathy in systemic lupus erythematosus. Clin Rheumatol 2008;27(10):1325–1328.PubMedCrossRefGoogle Scholar
  37. 37.
    Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn’s disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther 1996;10(3):321–326.PubMedCrossRefGoogle Scholar
  38. 38.
    Dansinger ML, Johnson S, Jansen PC, Opstad NL, Bettin KM, Gerding DN. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case–control study. Clin Infect Dis 1996;22(6):932–937.PubMedCrossRefGoogle Scholar
  39. 39.
    Ferrante M, Penninckx F, De Hertogh G, Geboes K, D’Hoore A, Noman M, Vermeire S, Rutgeerts P, Van Assche G. Protein-losing enteropathy in Crohn’s disease. Acta Gastroenterol Belg 2006;69(4):384–389.PubMedGoogle Scholar
  40. 40.
    Steinfeld JL, Davidson JD, Gordon RS Jr, Greene FE. The mechanism of hypoproteinemia in patients with regional enteritis and ulcerative colitis. Am J Med 1960;29:405–415.PubMedCrossRefGoogle Scholar
  41. 41.
    Baert D, Wulfrank D, Burvenich P, Lagae J. Lymph loss in the bowel and severe nutritional disturbances in Crohn’s disease. J Clin Gastroenterol 1999;29(3): 277–279.PubMedCrossRefGoogle Scholar
  42. 42.
    Maiden L. Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J Gastroenterol 2009;44 (Suppl 19):64–71. Epub 2009 Jan 16. Review.PubMedCrossRefGoogle Scholar
  43. 43.
    Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2005;21(2):169–175.PubMedCrossRefGoogle Scholar
  44. 44.
    Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009;44 (Suppl 19):23–29. Epub 2009 Jan 16.PubMedCrossRefGoogle Scholar
  45. 45.
    Liu NF, Lu Q, Wang CG, Zhou JG. Magnetic resonance imaging as a new method to diagnose protein losing enteropathy. Lymphology 2008;41(3):111–115.PubMedGoogle Scholar
  46. 46.
    Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann’s disease). Orphanet J Rare Dis 2008;3:5. Review.PubMedCrossRefGoogle Scholar
  47. 47.
    MacLean JE, Cohen E, Weinstein M. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy. Pediatrics 2002;109(6): 1177–1180.PubMedCrossRefGoogle Scholar
  48. 48.
    Nikolaidis N, Tziomalos K, Giouleme O, Gkisakis D, Kokkinomagoulou A, et al. Protein-losing enteropathy as the principal manifestation of constrictive pericarditis. J Gen Intern Med 2005;20(10):C5–C7.PubMedCrossRefGoogle Scholar
  49. 49.
    Ryerson L, Goldberg C, Rosenthal A, Armstrong A. Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation. Am J Cardiol 2008;101(2):248–251.PubMedCrossRefGoogle Scholar
  50. 50.
    Pratz KW, Dingli D, Smyrk TC, Lust JA. Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemia. Medicine (Baltimore) 2007;86(4):210–214.CrossRefGoogle Scholar
  51. 51.
    Karbach U, Ewe K, Bodenstein H. Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn’s disease. Gut 1983;24(8):718–723.PubMedCrossRefGoogle Scholar
  52. 52.
    Keller KM, Knobel R, Ewe K. Fecal alpha 1-antitrypsin in newborn infants. J Pediatr Gastroenterol Nutr 1997;24(3):271–275.PubMedCrossRefGoogle Scholar
  53. 53.
    Schmidt PN, Blirup-Jensen S, Svendsen PJ, Wandall JH. Characterization and quantification of plasma proteins excreted in faeces from healthy humans. Scand J Clin Lab Invest 1995;55(1):35–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Aslam, N. Wright R. Protein-losing enteropathy: differential diagnoses and workup. emedicine from WebMD. Updated July 11, 2008. Available at
  55. 55.
    Takeda H, Nishise S, Furukawa M, Nagashima R, Shinzawa H, Takahashi T. Fecal clearance of alpha1-antitrypsin with lansoprazole can detect protein-losing gastropathy. Dig Dis Sci 1999;44(11):2313–2318.PubMedCrossRefGoogle Scholar
  56. 56.
    Florent C, Vidon N, Flourie B, Carmantrand A, Zerbani A, et al. Gastric clearance of alpha-1-antitrypsin under cimetidine perfusion. New test to detect protein-losing gastropathy? Dig Dis Sci 1986;31(1):12–15.Google Scholar
  57. 57.
    Udall JN, Walker WA. Intestinal permeability in the newborn. In: Tanner MS, Stocks RJ, eds. Neonatal gastroenterology―contemporary issues. Newcastle Upon Tyne:. Scholium Int 1984:93–109.Google Scholar
  58. 58.
    Lisowska-Myjak B, Pachecka J, Antoniewicz B, Krawczyk A, Jozwik A. Alpha-1-antitrypsin, albumin and whole protein in meconium and stools during the first days of life in the neonate. Pediatr Pol 1995;70(10):819–826.PubMedGoogle Scholar
  59. 59.
    Vardy PA, Lebenthal E, Shwachman H. Intestinal lymphangiectasia: a reappraisal. Pediatrics 1975;55(6):842–851.PubMedGoogle Scholar
  60. 60.
    Aoki T, Noma N, Takajo I, Yamaga J, Otsuka M, Yuchi H, et al. Protein-losing gastropathy associated with autoimmune disease: successful treatment with prednisolone. J Gastroenterol 2002;37(3):204–209.PubMedCrossRefGoogle Scholar
  61. 61.
    Seok JW, Kim S, Lee SH, et al. Protein-losing enteropathy detected on Tc-99m HSA and 99mTc-MDP scintigraphy. Clin Nucl Med 2002;27(6): 431–433.PubMedCrossRefGoogle Scholar
  62. 62.
    Moy L. Levine J. Wireless capsule endoscopy in the pediatric age group: experience and complications. J Pediatr Gastroenterol Nutr 2007;44(4):516–520.PubMedCrossRefGoogle Scholar
  63. 63.
    Costamagna G, Shah SK, Riccioni ME, et al. A prospective trial comparing small bowel radiographs and video capsule endoscopy for suspected small bowel disease. Gastroenterology 2002;123(4):999–1005.PubMedCrossRefGoogle Scholar
  64. 64.
    Rivet C, Lapalus MG, Dumortier J, Le Gall C, Budin C, Bouvier R, et al. Use of capsule endoscopy in children with primary intestinal lymphangiectasia. Gastrointest Endosc 2006;64:649–650.PubMedCrossRefGoogle Scholar
  65. 65.
    Safatle-Ribeiro AV, Iriya K, Couto DS, Kawaguti FS, Retes F, et al. Secondary lymphangiectasia of the small bowel: utility of double balloon enteroscopy for diagnosis and management. Dig Dis 26(4):383–386, 2008. Epub 2009 Jan 30.PubMedCrossRefGoogle Scholar
  66. 66.
    Masetti PS, Marianeschi A, Capriani A, et al. Reversal of protein-losing enteropathy after ligation of systemic–pulmonary shunt. Ann Thorac Surg 1999;67: 235–236.PubMedCrossRefGoogle Scholar
  67. 67.
    Menon S, Hagler D, Cetta F, Gloviczki P, Driscoll D. Role of caval venous manipulation in treatment of protein-losing enteropathy. Cardiol Young 2008;18(3): 275–281.PubMedCrossRefGoogle Scholar
  68. 68.
    Jacobs ML, Rychik J, Byrum CJ, Norwood WI. Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration. Ann Thorac Surg 1996;61(1):206–208.PubMedCrossRefGoogle Scholar
  69. 69.
    Meyenberger C, Altorfer J, Munch R, Muller A, Ammann R. Long-term therapy of Menetrier disease using ranitidine and pirenzepine. Schweiz Med Worchenschr 1991;121(23):877–880.Google Scholar
  70. 70.
    Overholt BF, Jefferies GH. Hypertrophic, hypersecretory protein-losing gastropathy. Gastroenterology 1979;58:80–87.Google Scholar
  71. 71.
    Gadour MO, Salman AH, El Samman el Tel W, Tadros NM. Menetrier’s disease: an excellent response to octreotide. A case report from the Middle East. Trop Gastroenterol 2005;26(3):129–131.PubMedGoogle Scholar
  72. 72.
    Burdick JS, Chung E, Tanner G, Sun M, et al. Treatment of Ménétrier’s disease with a monoclonal antibody against the epidermal growth factor receptor. N Engl J Med 2002;343(23):1697–1701.CrossRefGoogle Scholar
  73. 73.
    Blackstone MM, Mittal MK. The edematous toddler: a case of pediatric Menetrier disease. Pediatr Emerg Care 2008;24(10):682–684.PubMedCrossRefGoogle Scholar
  74. 74.
    Prakash K, Varma D, Mahadevan P, Narayanan RG, Philip M. Surgical treatment for small bowel Crohn’s disease: an experience of 28 cases. Indian J Gastroenterol 2008;27(1):12–15.PubMedGoogle Scholar
  75. 75.
    Tift WL, Lloyd JK. Intestinal lymphangiectasia. Long-term results with MCT diet. Arch Dis Child 1975;50(4):269–276.PubMedCrossRefGoogle Scholar
  76. 76.
    Aoyagi K, Iida M, Matsumoto T, Sakisaka S. Enteral nutrition as a primary therapy for intestinal lymphangiectasia: value of elemental diet and polymeric diet compared with total parenteral nutrition. Dig Dis Sci 2005;50(8):1467–1470.PubMedCrossRefGoogle Scholar
  77. 77.
    Ossandon A, Bombardieri M, Coari G, Graziani G, Valesini G. Protein losing enteropathy in systemic lupus erythematosus: role of diet and octreotide. Lupus 2002;11(7):465–466.PubMedCrossRefGoogle Scholar
  78. 78.
    Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 2005;12(1):48–53.PubMedCrossRefGoogle Scholar
  79. 79.
    Kuroiwa G, Takayama T, Sato Y, Takahashi Y, Fujita T. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol 2001;36(2): 129–132.PubMedCrossRefGoogle Scholar
  80. 80.
    Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998;10(8):699–702.PubMedGoogle Scholar
  81. 81.
    Lee HL, Han DS, Kim JB, Jeon YC, Sohn JH, et al. Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report. J Korean Med Sci 2004;19(3): 466–469.PubMedCrossRefGoogle Scholar
  82. 82.
    Wang J, Zheng H, Sung CC, Hauer-Jensen M. The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys 1999;45(5):1289–1296.PubMedCrossRefGoogle Scholar
  83. 83.
    Bac DJ, Van Hagen PM, Postema PT, ten Bokum AM, Zondervan PE, et al. Octreotide for protein-losing enteropathy with intestinal lymphangiectasia. Lancet 1995;345(8965):1639.PubMedCrossRefGoogle Scholar
  84. 84.
    Bode L, Salvestrini C, Park PW, Li JP, Esko JD, et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008;118(1):229–238.PubMedCrossRefGoogle Scholar
  85. 85.
    Lencer WI. Patching a leaky intestine. N Engl J Med 2008;359(5):526–528.PubMedCrossRefGoogle Scholar
  86. 86.
    Liem YS, Bode L, Freeze HH, Leebeek FW, Zandbergen AA,et al. Using heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib. Nat Clin Pract Gastroenterol Hepatol 2008;5(4):220–224. Epub 2008 Feb 19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jonathan Goldstein
    • 1
  • Richard Wright
    • 2
  1. 1.Division of Gastroenterology/HepatologyUniversity of Louisville School of MedicineLouisvilleUSA
  2. 2.Division of Gastroenterology/HepatologyUniversity of Louisville School of MedicineLouisvilleUSA

Personalised recommendations